How long do patients with acute myeloid leukemia (AML) M5 typically survive?

Diseases caused by abnormalities in hematopoietic stem cells primarily involve uncontrolled proliferation of malignant cells, suppression of normal cellular proliferation, dysregulated apoptosis, and impaired growth of normal bone marrow hematopoietic cells. So, how long do patients with acute monocytic leukemia (AML-M5) typically survive?

How long do patients with AML-M5 typically survive?

AML-M5, also known as acute monocytic leukemia or M5-type leukemia, generally results in survival of approximately six months if timely and aggressive chemotherapy is not administered clinically. This is because AML-M5 is highly aggressive. Without prompt and intensive chemotherapy, leukemic cells proliferate extensively within the bone marrow, suppressing normal hematopoiesis. Consequently, patients develop cytopenias—reductions in normal blood cell counts—and become susceptible to complications such as infection, hemorrhage, and anemia.

Such patients are at constant risk for life-threatening complications including septic shock, hypovolemic shock, and cardiac dysfunction. However, with timely and aggressive clinical treatment—especially when followed by hematopoietic stem cell transplantation (HSCT)—patients with AML-M5 can achieve long-term survival. HSCT helps restore normal hematopoietic and immune function, potentially leading to clinical cure and prolonged survival.

In daily life, it is advisable to maintain a balanced routine—avoiding excessive fatigue, exposure to cold, and sleep deprivation. Such lifestyle habits help preserve immune function and enhance resistance against pathogenic microorganisms, thereby effectively reducing the risk of developing leukemia. We hope this information has been helpful to you!